A Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015082-31

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the objective response rate (ORR) of ABT-888 in combination with Temozolomide (TMZ) compared to Pegylated Liposomal Doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.


Critère d'inclusion

  • Recurrent high grade serous ovarian cancer